Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis.

ABSTRACT:

Background

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been found to have potential hematopoietic effects in patients with heart failure (HF). However, these benefits have not been studied in patients with cardiac amyloidosis (CA). CA patients present with HF symptoms and often suffer from iron deficiency, which has a negative impact on erythropoiesis and leads to lower hemoglobin and hematocrit levels. We sought to determine the potential effects of SGLT2i on hematological parameters and functional capacity (FC) in CA patients.

Methods

A prospective analysis was conducted to compare the effects of SGLT2i in patients who received the best medical therapy (BMT) along with SGLT2i (n = 20), versus patients receiving only BMT without SGLT2i (n = 20) (historical contr

SUBMITTER: Ermolaev N 

PROVIDER: S-EPMC11951278 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature